23 Jul, 2026
According to Straits Research, the global hERG screening market size was valued at $8.23 billion in 2025 and is projected to grow from $8.97 billion in 2026 to $17.78 billion by 2034, registering a CAGR of 8.94% during the forecast period 2026–2034.
The human ether-a-go-go-related gene, or HERG, encodes the potassium ion channel alpha subunit protein Kvl1.1. It is utilized to support the heart's function. The cardiac action potential channels regulate the repolarizing current, facilitating the heartbeat. The regulatory authorities' essential prerequisite for submitting an investigational new medication is the HERG assessment. HERG screening tests include microelectrode arrays, manual/automatic patch clamp assays, HERG radioligand binding assays, and fluorescence polarization assays. The HERG current is monitored at various doses during an automated patch-clamp experiment. It is undertaken both before and after exposure to the test drugs. The IC50 values are then calculated using a method known as dosage formulation analysis.
Heart disease is the primary cause of death for both men and women worldwide. According to the American College of Cardiology, every 40 seconds or so, an American will suffer a myocardial infarction. According to emergency medical services, 356,461 Americans experienced cardiac arrest outside of a hospital in 2017; emergency medical services treatment was initiated in 52.00% of those cases. Only 18.7% of the patients exhibited a cardiac rhythm that might have been shocked by an AED, such as ventricular fibrillation or ventricular tachycardia, during their initial checkup. Adults made it 10.4% of the time to hospital discharge, while 8.4% had satisfactory functional status.
The prevalence of cardiovascular diseases can be attributed to sedentary lifestyles and common risk factors like hypertension, which can range from 28% in the United Arab Emirates to 41% in Libya and Morocco, and diabetes, which can range from 4% in the Islamic Republic of Iran to 19% in Sudan, and hypercholesterolemia, which can range from 14% in Lebanon to 52% in the Islamic Republic of Iran. In conclusion, the development of the drug discovery market will assist the growth of the hERG screening market due to the rise in the prevalence of heart illnesses.
Companies that manufacture products or have distributor partnerships with smaller companies operating in untapped markets. The markets in Russia and South Africa are untapped compared to those in China, India, or Brazil. Additionally, these nations are seeing an increase in heart disease. According to a 2016 research report, 23.8 million persons in India had ischemic heart disease. India recorded 1,6.5 million stroke cases in 2016. As a result of the rising predominance in these unexplored areas, firms have a lot of room to grow.
North America is the most significant revenue contributor and is anticipated to grow at a CAGR of 12.30% over the forecast period. The US and Canada comprise most of North America, divided into market sectors for Latin America and North America. According to the American College of Cardiology, every 40 seconds, a citizen of the United States will experience a myocardial infarction. In 2017, 356,460 Americans went through an out-of-hospital cardiac arrest; emergency medical services were called in 52% of those cases. Only 18.75% of the initial cardiac rhythms observed were shockable by an automated external defibrillator, ventricular tachycardia, or fibrillation. Adults were released from the hospital in 10.4% of cases, and 8.4% had good functional conditions.
Europe is predicted to exhibit a CAGR of 14.50% during the projected period. Europe's western and eastern regions comprise the majority of the market for HERG screening and are both regarded as significant contributors. In addition to the other countries in Western Europe, the requirement for hERG screening has been further divided into Germany, France, the United Kingdom, Italy, and Spain. These are included along with the other nations that make up Western Europe.
sales@straitsresearch.com